Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

MNPR

Monopar Therapeutics Inc

Nov 28 • 03:39PM ET

86.18

-1.18 -1.35 %

Healthcare • Biotechnology • USA • NASD

Peers: FATE MCRB AFMD ADAP EYPT ADVM CYCN CTMX XBIT CBIO

| Held by: VTI IWM VXF IWO VFMO VTWO IWC GSSC VTWG RSSL

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.44	Insider Own	30.14%	Shs Outstand	6.66M	Perf Week	3.83%
Market Cap	575.90M	Forward P/E	-	EPS next Y	-3.35	Insider Trans	-22.74%	Shs Float	4.67M	Perf Month	2.41%
Enterprise Value	432.29M	PEG	-	EPS next Q	-0.45	Inst Own	57.97%	Short Float	7.95%	Perf Quarter	152.36%
Income	-19.44M	P/S	-	EPS this Y	60.73%	Inst Trans	22.06%	Short Ratio	3.66	Perf Half Y	171.60%
Sales	0.00M	P/B	4.06	EPS next Y	-107.82%	ROA	-25.88%	Short Interest	0.37M	Perf YTD	291.73%
Book/sh	21.25	P/C	4.01	EPS next 5Y	11.21%	ROE	-26.54%	52W High	105.00 -17.92%	Perf Year	344.23%
Cash/sh	21.50	P/FCF	-	EPS past 3/5Y	-4.06% -15.56%	ROIC	-13.73%	52W Low	18.81 358.16%	Perf 3Y	595.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.98% 8.94%	Perf 5Y	235.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-73.48%	Oper. Margin	-	ATR (14)	7.67	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	56.10	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	53.37	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	56.10	EPS Q/Q	-30.26%	SMA20	2.56%	Beta	1.47	Target Price	111.77
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.48%	Rel Volume	0.81	Prev Close	87.36
Employees	16	LT Debt/Eq	0.00	Earnings	Nov 13 BMO	SMA200	74.39%	Avg Volume	101.28K	Price	86.18
IPO	Dec 19, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-5.36% -	Trades		Volume	82,436	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-14-25	Downgrade	Raymond James	Strong Buy → Outperform
Nov-10-25	Initiated	Leerink Partners	Outperform	$115
Oct-13-25	Initiated	Barclays	Overweight	$125
Sep-09-25	Initiated	BTIG Research	Buy	$87
Sep-03-25	Initiated	Raymond James	Strong Buy	$80
Sep-03-25	Initiated	Oppenheimer	Outperform	$77
Aug-26-25	Resumed	H.C. Wainwright	Buy	$70
Jul-07-25	Initiated	Cantor Fitzgerald	Overweight	$74
Jun-23-25	Initiated	Chardan Capital Markets	Buy	$60
Mar-19-25	Resumed	Piper Sandler	Overweight	$76
Jan-10-25	Initiated	Piper Sandler	Overweight	$72
Oct-11-24	Initiated	Rodman & Renshaw	Buy	$50
Jan-28-21	Initiated	ROTH Capital	Buy	$49

Show Previous Ratings

Nov-13-25 08:00AM	Monopar Therapeutics Reports Third Quarter 2025 Financial Results and Recent Developments (GlobeNewswire) +5.36%
Nov-10-25 09:39AM	Coinbase upgraded, Six Flags downgraded: Wall Street's top analyst calls (The Fly)
Nov-09-25 09:00AM	Monopar Presents New Data and Analyses on Rapidly Improved Copper Balance in Wilson Disease Patients on Tiomolybdate Choline at AASLD - The Liver Meeting 2025 (GlobeNewswire)
Oct-21-25 09:55AM	Does Monopar Therapeutics (MNPR) Have the Potential to Rally 42.46% as Wall Street Analysts Expect? (Zacks)
Oct-16-25 04:33PM	Raymond James Boosts Monopar Therapeutics (MNPR) PT to $142, Maintains Strong Buy (Insider Monkey) -8.69%
08:00AM	Loading…
Oct-15-25 08:00AM	Monopar Announces Abstract Accepted for Oral Presentation at AASLD - The Liver Meeting 2025 (GlobeNewswire) -5.11%
Sep-23-25 11:08PM	Monopar Therapeutics Inc. Announces Pricing of $135 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +6.30% +7.94%
11:07PM	Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients (GlobeNewswire)
09:40AM	CoreWeave upgraded, Lululemon downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-25 01:15PM	Why Monopar Therapeutics, A Top 1% Biotech Stock, Just Surged Into A Breakout (Investor's Business Daily) +10.71%
Sep-14-25 08:00AM	Monopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual Meeting (GlobeNewswire)
Sep-03-25 08:00AM	Monopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual Meeting (GlobeNewswire) +6.72%
Aug-12-25 08:00AM	Monopar Therapeutics Reports Second Quarter 2025 Financial Results and Recent Developments (GlobeNewswire) +14.55%
Jun-26-25 03:24PM	Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy (Insider Monkey) +9.68%
Jun-11-25 09:55AM	Wall Street Analysts Predict a 51.26% Upside in Monopar Therapeutics (MNPR): Here's What You Should Know (Zacks)
07:00AM	Loading…
07:00AM	Monopar and EDNOC Announce Expanded Access Program for MNPR-101-Zr and MNPR-101-Lu in Advanced Cancers (GlobeNewswire)
Jun-06-25 09:40AM	Salesforce initiated, Dollar Tree upgraded: Wall Streets top analyst calls (TipRanks)
Jun-03-25 07:00AM	Monopar Therapeutics Announces Inclusion in the Russell 3000 and Russell 2000 Indexes (GlobeNewswire) +7.00%
May-13-25 08:00AM	Monopar Therapeutics Reports First Quarter 2025 Financial Results and Recent Developments (GlobeNewswire)
May-07-25 02:30AM	Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 (GlobeNewswire)
Apr-30-25 05:37AM	Why Monopar Therapeutics Inc. (MNPR) is Surging in 2025 (Insider Monkey)
Apr-29-25 08:00AM	Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 (GlobeNewswire)
Mar-31-25 08:00AM	Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments (GlobeNewswire) -9.72%
Mar-21-25 08:50AM	Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going (Zacks) -10.59%
Feb-03-25 07:22PM	Why Monopar Therapeutics Inc (MNPR) Is Skyrocketing So Far In 2025 (Insider Monkey) +10.22%
Jan-23-25 01:10PM	Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics (PR Newswire) +16.78%
07:06AM	Monopar Therapeutics price target raised to $40 from $22 at H.C. Wainwright (TipRanks)
Dec-31-24 02:36AM	These 2 Monster Growth Stocks Skyrocketed Over 1,000% This Year Heres What Analysts Expect in 2025 (TipRanks) -7.76%
Dec-20-24 09:00AM	Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants (GlobeNewswire) +8.53%
Dec-05-24 04:21PM	Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu (GlobeNewswire) -14.84%
08:00AM	Loading…
Dec-03-24 08:00AM	Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference (GlobeNewswire) +5.27%
Nov-08-24 08:00AM	Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments (GlobeNewswire) +7.31%
Oct-30-24 01:42PM	Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) -9.50%
Oct-28-24 09:15PM	Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock (GlobeNewswire) +5.32% -9.09%
04:00PM	Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-25-24 07:31AM	Monopar Therapeutics Secures License for Wilson Disease Treatment (TipRanks) -48.16%
Oct-24-24 07:00AM	Monopar Announces Agreement with Alexion, AstraZeneca Rare Disease For Late-Stage Wilson Disease Drug Candidate (GlobeNewswire) +605.40%
Oct-22-24 08:00AM	Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024 (GlobeNewswire)
Oct-16-24 08:28AM	Monopar Therapeutics Expands Portfolio with New Patent Filing (TipRanks)
Oct-15-24 08:00AM	Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers (GlobeNewswire)
Oct-08-24 08:30AM	Monopar Therapeutics Launches Phase 1a uPAR-Targeted Cancer Trial (TipRanks) +5.12%
Oct-07-24 08:00AM	Monopar Initiates Clinical Trial of Novel uPAR-Targeted Radiopharmaceutical Therapy in Advanced Cancers (GlobeNewswire) +10.20%
Sep-12-24 08:00AM	Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr (GlobeNewswire) +64.58%
Sep-04-24 08:00AM	Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-27-24 04:05PM	Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule (GlobeNewswire) -8.40% -5.83%
Aug-21-24 08:00AM	Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers (GlobeNewswire)
Aug-14-24 08:00AM	Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr (GlobeNewswire) -5.79%
Aug-12-24 12:24PM	Upcoming Stock Splits This Week (August 12 to August 16) Stay Invested (TipRanks) +6.56%
Aug-09-24 02:53PM	MNPR Stock Earnings: Monopar Therapeutics Misses EPS for Q2 2024 (InvestorPlace) -19.64%
08:00AM	Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments (GlobeNewswire)
08:00AM	Monopar Therapeutics Announces 1-for-5 Reverse Stock Split (GlobeNewswire)
Jul-09-24 07:00AM	Monopar Announces First Patient Enrolled in First-in-Human Phase 1 Trial for Its Novel Radiopharmaceutical MNPR-101-Zr (GlobeNewswire)
Jun-25-24 08:00AM	Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24 (GlobeNewswire)
Jun-11-24 07:30AM	Monopar and NorthStar Amend & Extend Collaboration (GlobeNewswire) +5.22%
Jun-10-24 08:00AM	Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting (GlobeNewswire)
Jun-05-24 06:15AM	Penny Stocks That Insiders Are Loading Up On: 3 Names to Watch Closely (InvestorPlace)
May-24-24 08:00AM	Monopar Announces CFO Succession (GlobeNewswire)
May-17-24 09:55AM	Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now (Zacks)
May-09-24 01:55PM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -5.19%
07:00AM	Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline (GlobeNewswire)
Apr-18-24 08:00AM	Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 08:00AM	Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings (GlobeNewswire)
Apr-10-24 08:00AM	Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients (GlobeNewswire) +8.36%
Apr-04-24 09:55AM	Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-03-24 12:00PM	All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy (Zacks)
Mar-28-24 11:53AM	MNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -7.60%
07:00AM	Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments (GlobeNewswire)
Mar-05-24 07:00AM	Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program (GlobeNewswire) +7.06%
Feb-27-24 07:00AM	Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial (GlobeNewswire) -10.37%
Feb-23-24 11:55AM	5 Best Rising Penny Stocks To Buy (Insider Monkey) +16.07%
Feb-22-24 07:00AM	Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers (GlobeNewswire) +96.49%
Feb-20-24 08:00AM	Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers (GlobeNewswire) +95.27%
Nov-09-23 08:37AM	Monopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical Programs (GuruFocus.com)
07:00AM	Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Nov-01-23 07:00AM	Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting (GlobeNewswire) +27.91%
Oct-10-23 07:00AM	Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference (GlobeNewswire) -5.96%
Sep-05-23 07:00AM	Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-10-23 07:00AM	Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments (GlobeNewswire)
Aug-08-23 07:00AM	Monopar Provides Encouraging Camsirubicin Clinical Data Update (GlobeNewswire) +15.22%
Jul-11-23 07:00AM	Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore (GlobeNewswire)
Jun-21-23 07:00AM	Monopar to Participate in the Radiopharma Forum by the Lake 2023 (GlobeNewswire)
Jun-14-23 07:00AM	Monopar to Participate in the Maxim Groups Healthcare Virtual Conference (GlobeNewswire)
Jun-01-23 07:00AM	Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update (GlobeNewswire) +7.36%
May-29-23 09:55AM	Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-11-23 07:00AM	Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments (GlobeNewswire) -6.58%
Apr-19-23 09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Mar-28-23 01:40PM	Monopar Therapeutics Shelves Development Of Validive For Radiation Therapy-Related Complication (Benzinga) -51.34%
07:00AM	Monopar to Present at the Jefferies Radiopharma Innovation Summit (GlobeNewswire)
Mar-27-23 05:00PM	Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis (GlobeNewswire)
Mar-23-23 07:00AM	Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments (GlobeNewswire)
Mar-07-23 07:00AM	Monopar to Present at the 35th Annual Roth Conference (GlobeNewswire)
Feb-27-23 07:00AM	Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials (GlobeNewswire)
Feb-14-23 12:46PM	What's Going On With Monopar Therapeutics Shares Today? (Benzinga)
07:00AM	Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin (GlobeNewswire)
Feb-05-23 08:38AM	We're Keeping An Eye On Monopar Therapeutics' (NASDAQ:MNPR) Cash Burn Rate (Simply Wall St.)
Jan-26-23 07:00AM	Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT (GlobeNewswire)
Jan-18-23 07:00AM	Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2 (GlobeNewswire)
Dec-12-22 07:00AM	Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration (GlobeNewswire) -18.97%
Nov-18-22 01:10PM	Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data (Zacks) -6.42%
09:55AM	Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Tactic Pharma LLC	10% Owner	Sep 24 '25	Sale	63.61	550,229	34,999,957	272,026	Sep 26 03:53 PM
Tsuchimoto Kim R	Director	Jul 14 '25	Sale	40.00	8,904	356,171	11,486	Jul 16 09:06 PM
STARR CHRISTOPHER M	Director	Jul 14 '25	Sale	40.00	16,800	672,020	5,173	Jul 16 09:03 PM
Robinson Chandler	Chief Executive Officer	Jul 14 '25	Sale	40.00	16,800	672,020	73,472	Jul 16 09:02 PM
STARR CHRISTOPHER M	Director	Jul 14 '25	Proposed Sale	40.00	16,800	672,000		Jul 14 12:29 PM
Tsuchimoto Kim R	Director	Jul 14 '25	Proposed Sale	40.00	8,904	356,160		Jul 14 12:26 PM
Robinson Chandler	Officer	Jul 14 '25	Proposed Sale	40.00	16,800	672,000		Jul 14 12:21 PM
Tactic Pharma LLC	10% Owner	Apr 02 '25	Sale	35.00	33,334	1,166,690	822,255	Apr 04 07:27 PM
Tactic Pharma LLC	10% Owner	Apr 02 '25	Proposed Sale	35.00	33,334	1,166,806		Apr 02 11:45 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

MNPR

Monopar Therapeutics Inc

Upgrade your FINVIZ experience